Results 211 to 220 of about 8,198,133 (306)

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies. [PDF]

Mol Ther Oncol
Visser N, González-Corrales M, Álvarez-Freile J, Pruis MG, Rockstein L, Lourens HJ, Schuringa JJ, van Meerten T, Huls G, Bremer E.   +9 more
europepmc   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

Fulminant Myocarditis Secondary to Cardiac T-Cell Lymphoma. [PDF]

JACC Case Rep
Wang Y, Li H, Gao S, Liu Y, Li L, Han Z, Wang Y, Zhang P, Yin H, He R.   +9 more
europepmc   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas. [PDF]

Blood Adv
Poh C, Voutsinas JM, Shadman M, Lynch RC, Warren EH, Crimp CA, Till BG, Ujjani CS, Di M, Raghunathan V, Smith SD, Wu QV, Shinohara MM, Gopal AK.   +13 more
europepmc   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source

Remote Force Modulation of the T-Cell Receptor Reveals an NFAT-Threshold for CD4⁺ T-Cell Activation. [PDF]

Eur J Immunol
Clarke J, Pike J, Bending D, Owen D, Wraith DC, Haj AJE.   +5 more
europepmc   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Microbiota-dependent metabolites - New engine for T cell warriors. [PDF]

Gut Microbes
Tang Y, Fu A, Wang L, Ge Q.
europepmc   +1 more source